Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$48.68 USD
+1.20 (2.53%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $48.68 0.00 (0.00%) 7:56 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.68 USD
+1.20 (2.53%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $48.68 0.00 (0.00%) 7:56 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Legend Biotech Corporation Sponsored ADR (LEGN) Soars 19.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Legend Biotech Corporation Sponsored ADR (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations
by Zacks Equity Research
Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.
Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 14.2%: Will It Continue to Soar?
by Zacks Equity Research
Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
by Zacks Equity Research
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Legend Biotech Corporation Sponsored ADR (LEGN) Soars 10.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 7.8%: Will It Continue to Soar?
by Zacks Equity Research
Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data
by Zacks Equity Research
Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.
Moving Average Crossover Alert: Legend Biotech (LEGN)
by Zacks Equity Research
Legend Biotech (LEGN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Are Options Traders Betting on a Big Move in Legend Biotech (LEGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Legend Biotech (LEGN) stock based on the movements in the options market lately.
Legend Biotech (LEGN) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Legend Biotech (LEGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
How to Tap the Booming IPO Market With ETFs
by Sweta Killa
The U.S. IPO market is red hot with some of the largest and most highly anticipated new listings hitting the market this week.